Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio
Biogen beat second-quarter earnings and revenue estimates, raised its 2026 guidance, and reported pipeline progress.
Biogen made more money than expected this quarter and feels confident enough to promise even better results next year, especially from its brain-disease and rare-disease medicines. When a company beats its targets and raises its outlook, that's a signal investors are watching to see if the company's products are really helping patients and selling well.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.